Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Two Considerations - 80% of Revenue going to TPL..a quick look at the last
24
Mar 24, 2010 11:58AM
8
Mar 24, 2010 12:50PM
1
Mar 24, 2010 01:05PM
3
Mar 24, 2010 01:43PM
2
Mar 24, 2010 01:56PM
4
Mar 24, 2010 04:10PM
1
Mar 24, 2010 04:36PM

This is why I keep saying "currently" - as in the policy at the moment in time of the AMS. I have heard from attendees about the 80/20 thing. And they seemed to believe that it is as I suggest, and really didn't have a problem with it. It's obvious that Alliacense was running short of funding for operations due to the pull-back of licensing activity. Hence the infusion from PTSC, and the loan from PTSC to TPL so they (TPL) could make their like contribution.

Certainly, with increased licensing revenues, the Alliacense funding policy will adjust accordingly. IMO, this policy was put in place temporarily until things happen (PTO) and licensing activity escalates. Again, IMO it is essential that they keep Alliacense running with a full head of steam. Failure to maintain that steam would truly be a failure in their fiduciary responsibility.

JMHOs,

SGE

5
Mar 24, 2010 05:52PM
2
Mar 24, 2010 06:21PM
6
Mar 24, 2010 07:02PM
1
Mar 24, 2010 08:21PM
Share
New Message
Please login to post a reply